Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.53 |
| ▸ | HTR1A | P08908 | 11/20 | 0.53 |
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | HTR7 | P34969 | 6/20 | 0.53 |
| ▸ | HTR6 | P50406 | 6/20 | 0.53 |
| ▸ | HTR2A | P28223 | 5/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30375406 | 1.00 | SLC6A4 (0.53) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL30375994 | 0.92 | KCNA5 (0.49) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL25759401 | 0.92 | KCNA5 (0.49) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL25759383 | 0.89 | KCNA5 (0.61) | SLC6A4DRD2HTR7HTR2AKCNA5 | |
| SCHEMBL30376202 | 0.89 | KCNA5 (0.61) | SLC6A4DRD2HTR7HTR2AKCNA5 | |
| SCHEMBL30375766 | 0.85 | KCNA5 (0.60) | SLC6A4DRD2HTR7HTR2AKCNA5 | |
| SCHEMBL25759431 | 0.85 | KCNA5 (0.60) | SLC6A4DRD2HTR7HTR2AKCNA5 | |
| SCHEMBL8876721 | 0.80 | HTR6 (0.62) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL23649454 | 0.79 | HTR1A (0.54) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL9031074 | 0.77 | HTR1A (0.47) | SLC6A4HTR1ADRD2HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | claimed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | SLC6A4 3/4885HTR1A 34/4885DRD2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.